Prostate cancer is one of the diseases worldwide that causes cancer-related deaths in men. Metformin is an antidiabetic drug that has been in use for over two decades for the treatment of Type II Diabetes mellitus (DM2). The purpose of this study was to evaluate the anti-proliferative property of metformin hydrochloride on androgen-sensitive, LNCAP and androgen-insensitive, PC-3 human prostate cancer cell lines at different concentrations (µM and mM) using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Metformin hydrochloride displayed a stronger cytotoxicity on the androgen-insensitive PC-3 than on the androgen-sensitive human prostate cancer cell lines. For both cell lines, the antiproliferative activity of metformin hydrochloride was best displayed at 0.1 mM concentration with average cell death percentage of 60% after 120-hour exposure.
Introduction
Prostate cancer is one of the foremost diseases worldwide that causes cancer-related deaths in men. It is the second most common noncutaneous cancer that affects thousands of men each year in the United States and occurs in older men above the age of 65 years. Every year, 20.7 per 100,000 men per year die of prostate cancer and one out of nine men is diagnosed with prostate cancer. It was estimated that 26,120 (4.4%) with prostate cancer will die in 2016 out of 180,890 new cases diagnosed [1] . Type II diabetes mellitus (DM2) is a common disease that affects about 9.3% (29 million) of people aged 20 years or older in the United States [2] [3] . Metformin, which belongs to the biguanide family, has been used for over two decades as the first line oral therapy for DM2 due to its clinical efficacy and low toxicity profile. The drug suppresses the hepatic glucose production through a mild and transient inhibition of the mitochondrial respiratory chain complex I [4] . This leads to the activation of AMPK (AMP-activated protein kinase). This effect has been suggested that metformin inhibits cancer cell proliferation and induces apoptosis by decreasing the energy disposition due to AMP: ATP ratio elevation and AMPK activation which can suppress tumor formation [5] . Different epidemiology studies have suggested that there is a decrease in the incidence and mortality rate of different cancers with the use of metformin. Case-control studies revealed that new users of metformin have a low risk of developing cancer [6] [7] [8] [9] . In this study, we describe findings supporting the antiproliferative property of metformin hydrochloride on human prostate cancer cell lines, LNCaP and PC-3.
Method
In Vitro Antiproliferative Assay 
Results and Discussion
Antiproliferation activity using MTT assay was used to determine the anticancer activity of metformin hydrochloride, an antidiabetic drug. The results indicated that the activity of metformin hydrochloride uses both dose-and time-dependents cytotoxicity (Figure 1 ).
The average cell death ranging between 20% and 60% was observed when androgen-dependent, LNCaP, and androgen-independent, PC-3, human prostate 
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